Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Thiethylperazine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 known ✓ | P14416 | 6/20 | 0.83 |
| ▸ | HRH1 | P35367 | 7/20 | 0.83 |
| ▸ | HTR1A | P08908 | 6/20 | 0.83 |
| ▸ | ADRA2A | P08913 | 6/20 | 0.83 |
| ▸ | ADRA2C | P18825 | 6/20 | 0.83 |
| ▸ | SLC6A2 | P23975 | 6/20 | 0.83 |
| ▸ | HTR2A | P28223 | 6/20 | 0.83 |
| ▸ | SLC6A4 | P31645 | 6/20 | 0.83 |
| ▸ | ADRA1A | P35348 | 6/20 | 0.83 |
| ▸ | DRD3 | P35462 | 6/20 | 0.83 |
| ▸ | SLC6A3 | Q01959 | 6/20 | 0.83 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.83 |
| ▸ | DRD1 | P21728 | 5/20 | 0.83 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.83 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.83 |
| ▸ | PDE4D | Q08499 | 4/20 | 0.83 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.83 |
| ▸ | MC3R | P41968 | 3/20 | 0.83 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.83 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.83 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Thiethylperazine SCHEMBL17079861 | 1.00 | HRH1 (0.83) | HRH1HTR1AADRA2ADRD2ADRA2C | |
| Thiethylperazine SCHEMBL29430925 | 1.00 | HRH1 (0.83) | HRH1HTR1AADRA2ADRD2ADRA2C | |
| Thiethylperazine SCHEMBL10624613 | 1.00 | HRH1 (0.83) | HRH1HTR1AADRA2ADRD2ADRA2C | |
| Thiethylperazine SCHEMBL30903918 | 1.00 | HRH1 (0.83) | HRH1HTR1AADRA2ADRD2ADRA2C | |
| Thiethylperazine SCHEMBL41676 | 1.00 | HRH1 (0.83) | HRH1HTR1AADRA2ADRD2ADRA2C | |
| Thiethylperazine SCHEMBL29688372 | 0.91 | HTR1A (1.00) | HRH1HTR1AADRA2ADRD2ADRA2C | |
| Thiethylperazine SCHEMBL29507072 | 0.91 | HTR1A (1.00) | HRH1HTR1AADRA2ADRD2ADRA2C | |
| Thiethylperazine SCHEMBL49124 | 0.91 | HTR1A (1.00) | HRH1HTR1AADRA2ADRD2ADRA2C | |
| Thiethylperazine SCHEMBL41677 | 0.91 | ADRA2A (0.80) | HRH1HTR1AADRA2ADRD2ADRA2C | |
| SCHEMBL22025181 | 0.90 | HRH1 (0.68) | HRH1HTR1AADRA2ADRD2ADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 833 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250082647-A1 | SPECIFIC DOSAGE OF PHENOTHIAZINE COMPOUNDS FOR USE IN TREATMENT OR PREVENTION OF ALZHEIMER'S DEMENTIA | IMMUNGENETICS AG (DE) | 2025-03-13 | — | — | US | claimed |
| WO-2023131606-A1 | SPECIFIC DOSAGE OF PHENOTHIAZINE COMPOUNDS FOR USE IN TREATMENT OR PREVENTION OF ALZHEIMER'S DEMENTIA | IMMUNGENETICS AG (DE) | 2023-07-13 | — | — | WO | claimed |
| CN-114053207-A | Sustained-release pharmaceutical composition and preparation method thereof | 常州恒邦药业有限公司 | 2022-02-18 | — | — | CN | claimed |
| CN-114053206-A | Medicinal floating preparation and preparation method thereof | 常州恒邦药业有限公司 | 2022-02-18 | — | — | CN | claimed |
| US-20220008334-A1 | GASTRIC RETENTIVE DEVICES | CLEXIO BIOSCIENCES LTD. (IL) | 2022-01-13 | — | — | US | claimed |
| US-11147766-B2 | Gastric retentive devices | CLEXIO BIOSCIENCES LTD. (IL) | 2021-10-19 | — | — | US | claimed |
| US-20200164047-A1 | THERAPY AND DIAGNOSIS OF DISEASE CHARACTERIZED BY ALTERATIONS IN THE DNA DAMAGE RESPONSE | UNIVERSITÀ DEGLI STUDI DI MILANO (IT) | 2020-05-28 | — | — | US | claimed |
| EP-3642337-A1 | THERAPY AND DIAGNOSIS OF DISEASE CHARACTERIZED BY ALTERATIONS IN THE DNA DAMAGE RESPONSE | IFOM - Fondazione Istituto FIRC di Oncologia Molecolare (IT) | 2020-04-29 | — | — | EP | claimed |
| WO-2018211137-A1 | THERAPY AND DIAGNOSIS OF DISEASE CHARACTERIZED BY ALTERATIONS IN THE DNA DAMAGE RESPONSE | UNIVERSITÀ DEGLI STUDI DI MILANO (IT) | 2018-11-22 | — | — | WO | claimed |
| US-20170027975-A1 | Methods of Treating Coronavirus Infection | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2017-02-02 | — | — | US | claimed |
| US-20090004281-A1 | MULTIPARTICULATE OSMOTIC DELIVERY SYSTEM | BIOVAIL LABORATORIES INTERNATIONAL S.R.L. (BB) | 2009-01-01 | — | — | US | claimed |
| WO-2008001341-A1 | MULTIPARTICULATE OSMOTIC DELIVERY SYSTEM | BIOVAIL LABORATORIES INTERNATIONAL SRL (BB) | 2008-01-03 | — | — | WO | claimed |
| JP-2007516217-A | — | — | 2007-06-21 | — | — | JP | claimed |
| EP-1670427-A2 | METHODS AND REAGENTS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | CombinatoRx, Incorporated (US) | 2006-06-21 | — | — | EP | claimed |
| US-20050192261-A1 | Methods and reagents for the treatment of immunoinflammatory disorders | COMBINATORX INCORPORATED | 2005-09-01 | — | — | US | claimed |
| WO-2005027839-A2 | METHODS AND REAGENTS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | COMBINATORX, INCORPORATED (US) | 2005-03-31 | — | — | WO | claimed |
| US-5023088-A | Drug delivery dispenser | ALZA CORPORATION (US) | 1991-06-11 | — | — | US | claimed |
| EP-0180364-B1 | PHARMACEUTICAL COMPOSITIONS CONTAINING PHENOTHIAZINES | RECKITT AND COLMAN PRODUCTS LIMITED (GB) | 1990-03-07 | — | — | EP | claimed |
| EP-0180364-A2 | Pharmaceutical compositions containing phenothiazines | RECKITT AND COLMAN PRODUCTS LIMITED (GB) | 1986-05-07 | — | — | EP | claimed |
| US-4111203-A | OSMOTIC SYSTEM WITH MEANS FOR IMPROVING DELIVERY KINETICS OF SYSTEM | ALZA CORPORATION (US) | 1978-09-05 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250082647-A1 | SPECIFIC DOSAGE OF PHENOTHIAZINE COMPOUNDS FOR USE IN TREATMENT OR PREVENTION OF ALZHEIMER'S DEMENTIA | PSEN1, PSEN2, APP | DRD2 164/4885HRH1 310/4885HTR1A 69/4885 |
| US-20200164047-A1 | THERAPY AND DIAGNOSIS OF DISEASE CHARACTERIZED BY ALTERATIONS IN THE DNA DAMAGE RESPONSE | PPP3CA, PPP5C, PPP3R1 | DRD2 4849/4885HRH1 4391/4885HTR1A 4168/4885 |
| US-20050192261-A1 | Methods and reagents for the treatment of immunoinflammatory disorders | IL5, CMA1, CCL11 | DRD2 2151/4885HRH1 13/4885HTR1A 615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.